Nina Tandon, CEO of EpiBone appeared on CNBC last week, discussing the company’s technology allowing patients to grow new bones in a lab to help heal from injury, illness or surgery.
The Partnership Fund invested in EpiBone through our BioAccelerate funding program—which provides early stage funding to NYC-based biotech companies spun out of local academic institutions. Located in Brooklyn, at the SUNY Downstate incubator and spun out of Columbia University, EpiBone is engineering stem cells into anatomically precise and patient-specific implants for skeletal reconstruction.